İrem Bilgetekin

ORCID: 0000-0003-1154-5850
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Renal cell carcinoma treatment
  • Cancer Immunotherapy and Biomarkers
  • Bladder and Urothelial Cancer Treatments
  • Gastric Cancer Management and Outcomes
  • Colorectal Cancer Treatments and Studies
  • Cancer Treatment and Pharmacology
  • Hepatocellular Carcinoma Treatment and Prognosis
  • Metastasis and carcinoma case studies
  • Breast Cancer Treatment Studies
  • Lung Cancer Treatments and Mutations
  • Prostate Cancer Treatment and Research
  • Multiple and Secondary Primary Cancers
  • Viral-associated cancers and disorders
  • Ovarian cancer diagnosis and treatment
  • Advanced Breast Cancer Therapies
  • Cancer Genomics and Diagnostics
  • Cancer, Lipids, and Metabolism
  • Cholangiocarcinoma and Gallbladder Cancer Studies
  • Urinary and Genital Oncology Studies
  • Cancer, Hypoxia, and Metabolism
  • Cancer Diagnosis and Treatment
  • Chronic Myeloid Leukemia Treatments
  • Inflammatory Biomarkers in Disease Prognosis
  • HER2/EGFR in Cancer Research
  • Esophageal Cancer Research and Treatment

Ankara Onkoloji Eğitim ve Araştırma Hastanesi
2018-2025

Sağlık Bilimleri Üniversitesi
2019-2025

Memorial Ankara Hospital
2018-2024

Gazi University
2015-2024

Ministry of Health
2018-2020

Ankara Spine Center
2020

Güven Hospital
2020

Kutahya Saglik Bilimleri Universitesi
2019

Ali Osman Sonmez Oncology Hospital
2019

Erciyes University
2019

Aim: To investigate how COVID-19 fear and anxiety (COV-FA) affects chemotherapy adherence in patients with cancer. Materials & methods: The records of 3661 (CT) appointments were retrospectively reviewed. Results: CT postponement rates before after 11.6% 14.2%, respectively (p = 0.017). rate COV-FA-related telemedicine was lower than that (4.6% vs 17.4%; p 0.012). median time to come back treatment the COV-FA group 47 days (range 19–72 days). Advanced age (≥60 years) found be independent...

10.2217/fon-2020-0592 article EN Future Oncology 2020-07-17

708 Background: This study evaluates the real-world efficacy and safety of avelumab maintenance therapy in metastatic urothelial carcinoma (mUC) patients who have not progressed following first-line platinum chemotherapy, using data from EAP. Methods: The primary endpoint was overall survival (OS), progression-free (PFS) secondary endpoints included safety. PFS OS were estimated by Kaplan-Meier method. Results: One hundred seventeen received at least one cycle Avelumab. median number...

10.1200/jco.2025.43.5_suppl.708 article EN Journal of Clinical Oncology 2025-02-10

The identification of prognostic factors in patients with glioblastoma multiforme (GBM) represents an area increasing interest. Carbonic anhydrase IX (CA‐IX), a hypoxia marker, correlates tumor progression variety human cancers. However, the role CA‐IX GBM remains largely unknown. In present study, we evaluated patients. total, 66 consecutive who received concomitant chemoradiotherapy and adjuvant chemotherapy temozolomide were retrospectively reviewed, all for at least 3 months....

10.1111/neup.12485 article EN Neuropathology 2018-06-28

<b><i>Introduction:</i></b> The aim of the study was to evaluate impact systemic immune-inflammation index (SII) on prognosis and survival within International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) score groups. <b><i>Methods:</i></b> records 187 patients with metastatic renal cell carcinoma (RCC) were reviewed retrospectively. SII calculated as follows: = Neutrophil × Platelet/Lymphocyte. categorized into 2 groups based a...

10.1159/000513456 article EN Urologia Internationalis 2021-01-01

The prognosis of patients with advanced HCC can vary widely depending on factors such as the stage cancer, patient's overall health, and treatment regimens. This study aimed to investigate survival outcomes associated in hepatocellular carcinoma (HCC). In this retrospective study, data from 23 medical oncology clinics were analyzed. Progression-free (PFS) (OS) values estimated using Kaplan–Meier method. Prognostic which identified univariate analysis subsequently evaluated a multivariate...

10.1080/1120009x.2024.2305066 article EN Journal of Chemotherapy 2024-01-23

Membraneous nephropathy (MN) is the most commonly occurring nephrotic syndrome in adults as well common paraneoplastic associated with solid tumors, and it mostly gastrointestinal system lung carcinomas. Accurate diagnosis important treatment of glomerulonephritis very varied from that idiopathic ones. In current report, a case patient was referred proteinuria edema diagnosed cancer, responded markedly to malignancy, improvement MN, presented. Active cancer present all patients MN. numerous...

10.3892/mco.2017.1295 article EN Molecular and Clinical Oncology 2017-06-21

Abstract To compare enzalutamide (E) and abiraterone acetate (AA) in terms of efficacy, survival to characterize prognostic factors affecting metastatic castration-resistant prostate cancer (mCRPC) patients. A total 250 patients treated with E or AA 5 centers were included. The number no specific antigen (PSA) decline was higher the group than that group, proportion a PSA ≥ 50% (p = 0.020). Radiological progression free (rPFS) overall (OS) significantly longer when compared < 0.001 p...

10.1038/s41598-021-93659-x article EN cc-by Scientific Reports 2021-07-08

To investigate the role of surgical resection primary tumor on overall survival (OS) in advanced gastric cancer patients at time diagnosis.The rates metastatic whose was resected diagnosis were compared with nonresected.The median progression-free and OS operated nonoperated group 10 versus 6, 14 9 months, respectively (p < 0.001). In multivariate analysis, tumor, Eastern Cooperative Oncology Group performance status, second-line chemotherapy had a significant effect (hazard ratio [HR]: 0.52...

10.2217/fon.15.304 article EN Future Oncology 2016-01-18

Introduction To investigate the level of psychological resilience and impact attachment styles on degree to distress in patients with cancer receiving chemotherapy. Methods Patients chemotherapy were included study. Participants requested complete Relationship Scales Questionnaire (RSQ), Resilience Scale for Adults (RSA), a personal information form during data collection phase. One-way analysis variance (ANOVA) was used compare that parameter among styles. Logistic regression carried out...

10.7759/cureus.10954 article EN Cureus 2020-10-15

Adjuvant chemotherapy for gastric cancer in elderly patients has same benefits as younger

10.4103/0973-1482.172588 article EN Journal of Cancer Research and Therapeutics 2018-01-01

Amaç: Biz bu çalışmamızda tip 2 diabetes mellitus (DM) gelişiminde rol aldığı öne sürülen nflamasyon, oksidatif stres ve insülin direncini gösteren parametrelerin prediyabetik dönemdeki düzeylerinin, serum rezistin düzeyi ile olan ilişkisini araştırmayı amaçladık.Yöntemler: Rezistin; son yıllarda keşfedilmiş, yağ dokusundan salgılanan adipokindir.Son dönemde yapılan çalışmalar obeziteyle ilişkili insulin direncinde önemli rolünün olduğunu göstermiştir.Çalışmamıza

10.4274/btdmjb.galenos.2018.20180226011446 article TR Bakirkoy Tip Dergisi / Medical Journal of Bakirkoy 2019-02-27

Objective: To evaluate the prognostic role of systemic immune-inflammation index (SII), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte (PLR) in patients who received platin-pemetrexed combination therapy and/or maintenance pemetrexed therapy.

10.29271/jcpsp.2020.09.933 article EN Journal of College of Physicians And Surgeons Pakistan 2020-09-01

Pazopanib is an effective treatment for advanced renal cell carcinoma and soft tissue sarcoma. Besides classical adverse events of this drug class, hepatotoxicity has been described as a frequent side effect. The aim the present study was to evaluate effect pazopanib on liver in experimental rat model. Sixteen Wistar albino rats were divided into 3 groups: toxicity induced with (10 mg/kg) administered 28 days (group 2) or 56 3) orally by gavage. Group 1 (control group) received only...

10.1159/000481795 article EN Chemotherapy 2018-01-01

Aims: In this multicenter study, the authors aimed to determine real-life efficacy and safety of first-line alectinib. Materials & methods: This retrospective trial included advanced-stage, ALK-positive non-small-cell lung cancer patients who were treated with alectinib in terms ALK-tyrosine kinase inhibitors, regardless previous chemotherapy. The co-primary end points progression-free survival both for all treatment-naive population. secondary overall response rate, survival, rate CNS...

10.2217/fon-2022-0083 article EN Future Oncology 2022-06-23
Coming Soon ...